Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
IPO Year:
Exchange: AMEX
Website: brooklynitx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/29/2021 | $9.00 | Overweight | Cantor Fitzgerald |
| 10/6/2021 | $20.00 | Buy | Maxim Group |
SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief
Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensati
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of Susan McClatchey as Vice President, Head of Quality. "We are aggressively preparing to handle what we believe will be a rapid ramp-up of drug development activities through our gene editing/cell therapy platform, which will require specialized resources including quality assurance," commented Howard J. Federoff, M.D., Ph.D, Brooklyn's President and Chief Executive Offi
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021. "Roger's extensive R&D experience, including many years in late-stage clinical development involving a wide array of treatment modalities for hematologic malignancies and solid tumors, brings him to Brooklyn at an inflection point where his insight and understanding will help guide us to the
NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Jay Sial as its Chief Administrative Officer, effective July 15, 2021. "Jay has a long and impressive history managing the finances of multiple health systems and hospitals and leading the financial transformation of complex organizations through prudent management and strategic activities, including fundraising, business development and facilities management. We are tru
BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced the appointment of Kevin A. D’Amour, Ph.D. as its Chief Scientific Officer. Dr. D’Amour joins Brooklyn from ViaCyte, Inc., a private, clinical stage company developing stem cell-based therapy for type 1 and insulin-dependent type 2 diabetes, where he most recently served as Chief Scientific Officer. He holds more than 100 U.S. and international patents and has been wide
Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced the appointment of Michael Andreeff, M.D., Ph.D. to Brooklyn's Scientific Advisory Board, effective May 21, 2021. Dr. Andreeff currently serves as a Professor of Medicine at MD Anderson Cancer Center where he holds the Paul and Mary Haas Chair in Genetics and is the Chief of Molecular Hematology and Therapy. Dr. Andreeff received his M.D. and Ph.D. from the University of Heidelberg, Germany, and additional training at Memorial Sloan Kettering Cancer Cent
Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today announced the appointment of Erich Mohr, Ph.D., ICD.D. to Brooklyn's Board of Directors, effective May 7, 2021. "Dr. Erich Mohr's distinguished career as a leader of life sciences companies, as well as in academic research, will serve as an important resource to Brooklyn," said Howard J. Federoff, M.D., Ph.D. Brooklyn ImmunoTherapeutics' Chief Executive Officer and President. "Dr. Mohr has a proven track record of creating value both as a Board
Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Matthew During, M.D., Ph.D. to the Company's Scientific Advisory Board, effective April 26, 2021. Dr. During is a Harvard, MIT and Yale trained neuroscientist. He has served for 9 years as a member of the faculty of Yale as Professor of Neurosurgery, and as a Professor at Thomas Jefferson, Cornell, and Ohio State Universities. Dr. During was a pioneer in the use of viral vectors for neurological disorders, and was the first to carry out gene transfer into the brain of a
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company's shares to trade under new ticker symbol "ERNA" starting on October 17, 2022, and a one-for-twenty share consolidation will become effective on that date SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), today announces that it is changing its name to Eterna Therapeutics Inc. ("Eterna") to reflect its focus on developing advanced therapies using its extens
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company") today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity. The primary endpoint of the study was to estimate 2-year Event-Free Survival (EFS) with key secondary endpoints of Overall Survival (OS) and safety of IRX-2. One hundred and fifty patients were enrolled in the study. At two years of follow-up in the intention-to-treat (ITT, n=105) population the median EFS was 48.3 months and was not reached in the control arm (Hazard
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today announced that on June 17, 2022, it received a notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq"), stating that the Company is not in compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the Company's common stock for the 30 consecutive business days prior to the date of the Notice. The Notice has no imm
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the following appointments to the Board, effective June 5, 2022: Matt Angel, Ph.D., Interim Chief Executive Officer ("CEO") of Brooklyn and Co-Founder, Chairman, President and CEO of Factor Bioscience Inc.Gregory Fiore, Co-Founder, President, and CEO of Exacis BiotherapeuticsNicholas Singer, Founder and Managing Member of Purchase CapitalBill Wex
SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief
SAN DIEGO, May 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq"), stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the "Quarterly Report"), Brooklyn is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial rep
Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta
SAN DIEGO, April 21, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the establishment of a new corporate and research and development facility at The Boardwalk at Science Center Drive in San Diego, California to support translational R&D for cell therapies and genetic medicines. "The opening of our state-of-the-art, 5,200 square foot facility represents a significant achievement for Brooklyn as we look to expand upon our researc
SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the fourth quarter and year ended December 31, 2021. Financial and corporate highlights for the quarter and year months ended December 31, 2021 and subsequently include the following: Fourth quarter ended December 31, 2021: Appointed Susan McClatchey as Vice President and Head of QualityNamed to both the Nasdaq Biotechnology Index and the ICE Biotechnology Ind
NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it has closed its previously announced private placement with a leading healthcare investor. The gross proceeds to Brooklyn from the private placement, before deducting the placement agent's fees and other estimated fees and expenses related to the offering payable by Brooklyn, were approximately $12 million. Brooklyn intends to use the net proceeds from the private placement for g
Cantor Fitzgerald initiated coverage of Brooklyn with a rating of Overweight and set a new price target of $9.00
Maxim Group initiated coverage of Brooklyn ImmunoTherapeutics with a rating of Buy and set a new price target of $20.00
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the fourth quarter and year ended December 31, 2021. Financial and corporate highlights for the quarter and year months ended December 31, 2021 and subsequently include the following: Fourth quarter ended December 31, 2021: Appointed Susan McClatchey as Vice President and Head of QualityNamed to both the Nasdaq Biotechnology Index and the ICE Biotechnology Ind
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the quarter ended September 30, 2021. Financial and corporate highlights for the quarter ended September 30, 2021 and subsequently include the following: Transitioned from the NYSE American to the Nasdaq Global Market to better align with industry peersCompleted the acquisition of Novellus TherapeuticsAppointed Roger Sidhu, M.D. as chief medical officer, Jay Sial
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today provided highlights from a Shareholder Update Call conducted on September 20, 2021 by President and Chief Executive Officer Howard J. Federoff, M.D., Ph.D., with guest contributor Matt Angel, Ph.D., Factor Bioscience's Co-founder and Chief Executive Officer. The call was based on Brooklyn's most recent corporate slide deck, which can be found here. Highlights of the call included: Brooklyn
BROOKLYN, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it will host a shareholder update conference call on Thursday, August 19, 2021, at 4:30 p.m. ET. Participants are asked to pre-register for the call through the following link: https://dpregister.com/sreg/10159634/ec70e32616. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those who
NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that gene editing/cell and cytokine therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the quarter ended June 30, 2021. Financial and corporate highlights for the quarter ended June 30, 2021 and subsequently include the following: Completed the acquisition of Novellus Therapeutics Limited ("Novellus") in July 2021. Novellus is developing next-generation engineered mesenchymal stem cell ("MSC") therapies using patented mRNA-based cell reprog
Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy Company to hold Conference Call Today, July 19, 2021, at 4:15PM ET to Discuss the Transaction and Future Plans NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it had completed, on July 16, 2021, its acquisition of Novellus Therapeutics Limited ("Novellus"). Novellus is developing next-generation engineered mesenchymal stem
Brooklyn ImmunoTherapeutics LLC (NYSE:BTX) ("Brooklyn") today announced it has acquired an exclusive license for mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited pursuant to an exercise of a previously announced option. The license includes use of an extensively patented process to develop gene editing compounds using mRNA, which preclinical data suggest demonstrate a high degree of efficiency, as well as being non-immunogenic and non-mutagenic. The licensed platform includes mRNA cell reprogramming, which is considered to be the highest efficiency and footprint-free technology that can be applied to both allogeneic and autolog
8-K - Eterna Therapeutics Inc. (0000748592) (Filer)
424B3 - Eterna Therapeutics Inc. (0000748592) (Filer)
EFFECT - Eterna Therapeutics Inc. (0000748592) (Filer)
8-K - Eterna Therapeutics Inc. (0000748592) (Filer)
S-8 - Eterna Therapeutics Inc. (0000748592) (Filer)
S-3 - Eterna Therapeutics Inc. (0000748592) (Filer)
8-K - Eterna Therapeutics Inc. (0000748592) (Filer)
8-K - Eterna Therapeutics Inc. (0000748592) (Filer)
8-K - Eterna Therapeutics Inc. (0000748592) (Filer)
10-Q - Eterna Therapeutics Inc. (0000748592) (Filer)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
Maxim Group analyst Jason McCarthy downgrades Brooklyn (NASDAQ:BTX) from Buy to Hold.
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company's shares to trade under new ticker symbol "ERNA" starting on October 17, 2022, and a one-for-twenty share consolidation will become effective on that date
Monday saw 825 companies set new 52-week lows. Key Facts About Today's 52-Week Lows: Visa (NYSE:V) was the largest firm on a market cap basis to set a new 52-week low. The company with the smallest market cap to set a new 52-week low was Mobilicom (NASDAQ:MOB). Color Star Technology (NASDAQ:CSCW) shares dropped the most, trading down 3070.81% to reach its new 52-week low. Skillsoft (NYSE:SKIL) was the biggest winner of the bunch, with shares actually trading up 0.0% after it rebounded from its new 52-week low. On Monday, the following stocks hit new 52-week lows: Visa (NYSE:V) shares made a new 52-week low of $181.63 on Monday. The stock was down 0.94% for the day. Oracle (NY
On Thursday, 1076 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was Microsoft (NASDAQ:MSFT). The smallest company by market cap to hit a new 52-week low was First Wave BioPharma (NASDAQ:FWBI). TOP Ships (NASDAQ:TOPS) was the biggest loser, trading down 25.64% to reach its 52-week low. On Thursday, the following stocks set new 52-week lows: Microsoft (NASDAQ:MSFT) shares made a new 52-week low of $237.57 on Thursday. The stock was up 0.26% for the day. Alphabet (NASDAQ:GOOG) stock drifted up 0.17% on Thursday morning to hit a new 52-week low of $99.41. Alphabet (NASDAQ:GOOGL) shar
On Thursday, 168 companies reached new 52-week lows. Points of Interest From Today's 52-Week Lows: Verizon Communications (NYSE:VZ) was the biggest company on a market cap basis to set a new 52-week low. The smallest company by market cap to set a new 52-week low was Tenax Therapeutics (NASDAQ:TENX). MasterCraft Boat Hldgs (NASDAQ:MCFT) saw the most pronounced move, as shares traded down 14.36% to hit its new 52-week low. Semantix (NASDAQ:STIX) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. Stocks that set new 52-week lows on Thursday are as follows: Verizon Communications (NYSE:VZ) shares set a new yearly low of $40.71 this morning.
On Wednesday, 297 companies achieved new lows for the year. Things to Consider About Today's 52-Week Lows: Toyota Motor (NYSE:TM) was the largest firm by market cap to set a new 52-week low. The company with the smallest market cap to set a new 52-week low was Mobilicom (NASDAQ:MOB). NewAge (NASDAQ:NBEV)'s stock made the biggest move downwards, diving 22.72% to reach a new 52-week low. ACI Worldwide (NASDAQ:ACIW) was the most promising stock of the group, with shares actually trading up 0.0% to bounce back after reaching its new 52-week low. Stocks that set new 52-week lows on Wednesday are as follows: Toyota Motor (NYSE:TM) shares hit a yearly low of $140.96. The stock was do
On Friday, 122 stocks hit new 52-week lows. Facts of Interest About Today's 52-Week Lows: Sony Group (NYSE:SONY) was the biggest company by market cap to set a new 52-week low. The smallest company by market cap to set a new 52-week low was Reshape Lifesciences (NASDAQ:RSLS). PolyPid (NASDAQ:PYPD) was the biggest loser, trading down 77.01% to reach its 52-week low. Aveanna Healthcare Hldgs (NASDAQ:AVAH) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low. On Friday, the following stocks set new 52-week lows: Sony Group (NYSE:SONY) shares set a new 52-week low of $77.86. The stock traded down 0.32%. GSK (NYSE:GSK) stock broke to a new 52-week low
Gainers SenesTech (NASDAQ:SNES) stock rose 28.0% to $0.64 during Thursday's after-market session. The market value of their outstanding shares is at $7.8 million. Chembio Diagnostics (NASDAQ:CEMI) stock rose 14.06% to $0.73. Chembio Diagnostics's trading volume hit 558.2K shares by close, accounting for 49.6% of its average volume over the last 100 days. The market value of their outstanding shares is at $22.0 million. MyMD Pharmaceuticals (NASDAQ:MYMD) shares rose 10.51% to $3.68. The company's market cap stands at $140.0 million. Lixte Biotech Hldgs (NASDAQ:LIXT) shares rose 8.96% to $0.83. The company's market cap stands at $13.8 million. Brooklyn (NASDAQ:BTX) stock moved upwards by
During Friday's session, 132 stocks hit new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: AT&T (NYSE:T) was the largest firm on a market cap basis to set a new 52-week low. First Wave BioPharma (NASDAQ:FWBI) was the smallest firm by market cap to set a new 52-week low. First Wave BioPharma (NASDAQ:FWBI)'s stock moved significantly downwards, trading down 2705.16% to reach a new 52-week low. Treasure Global (NASDAQ:TGL)'s stock made the biggest bounce back, actually moving up 0.16% shortly after hitting a new 52-week low. Stocks dropping to new 52-week lows on Friday: Anheuser-Busch InBev (NYSE:BUD) shares reached a new 52-week low of $50.13 on Friday morning,